

Research Article

Impact of Successful Recanalization of Chronic Total Occlusions Using Coronary Stents on Long-Term Clinical Outcomes: A Meta-Analysis

Jang JS*

Department of Internal Medicine, University of Inje College of Medicine, Korea

***Corresponding author:** Jae-Sik Jang, Department of Internal Medicine, Busan Paik Hospital, University of Inje College of Medicine, 633-165 Gaegum-dong, Jin-gu, Busan, 614-735, Korea**Received:** December 12, 2016; **Accepted:** January 18, 2017; **Published:** January 24, 2017**Abstract**

Background and Objectives: Although coronary stent implantation dramatically reduced the occurrences of restenosis and the needs for repeat revascularization, there is still uncertainty as to the prognostic impact of successful recanalization of Chronic Total Occlusion (CTO) lesion. The objective of this study was to determine the impact of successful CTO recanalization using coronary stent deployment on clinical outcomes.

Subjects and Methods: Databases were searched for clinical studies that compared outcomes after successful recanalization of CTO lesions using coronary stent deployment with those of unsuccessful recanalization from January 2003 to March 2016. The end points of this study were mortality; Myocardial Infarction (MI); Major Adverse Cardiac Events (MACE); the need for Coronary Artery Bypass Graft Surgery (CABG); and angina relief at the longest follow-up.

Results: Nineteen studies encompassing 12,598 patients with a median follow-up period of 12-60 months after successful vs. unsuccessful CTO recanalization using coronary stent were identified. There were 455 (5.0%) deaths of 9,041 patients after successful recanalization compared to 339 (10.3%) among 3,280 patients after unsuccessful recanalization (odds ratio [OR] 0.48, 95% Confidence Interval [CI] 0.38 to 0.61). Successful CTO recanalization significantly reduced the incidence of MI (OR 0.67, 95% CI 0.46 to 0.97) and MACE (OR 0.55, 95% CI 0.42 to 0.73). Successful CTO recanalization was associated with a lower need for subsequent CABG and higher angina relief.

Conclusion: Successful recanalization of CTO lesions using coronary stents deployment appears to be associated with improvement in mortality and reduced needs for CABG as compared with unsuccessful PCI.

Keywords: Chronic total occlusion; Percutaneous coronary intervention; Stents

Introduction

Percutaneous Coronary Intervention (PCI) for Chronic Total Occlusion (CTO) of coronary arteries accounts for 10% to 20% of all PCI [1]. Increasing experience and advanced interventional technologies have increased success rate of CTO intervention up to 90% if performed by experts [2,3]. Moreover, successful recanalization of CTO reduces anginal symptom, risk of periprocedural Myocardial Infarction (MI), mortality, improve left ventricular function, and diminish subsequent needs for Coronary Artery Bypass Grafting (CABG) [3-6].

Although coronary stents implantation dramatically reduced the occurrence of restenosis and the need for repeat revascularization, there is still uncertainty as to the prognostic impact of successful CTO recanalization using coronary stents. Several previous studies evaluating long-term outcomes after CTO intervention have shown conflicting results regarding the benefit of opening CTO lesion [5,7-10]. Recent publication of several observational studies of CTO using coronary stents [11-15] have provided substantial evidences,

suggesting the need for an updated meta-analysis to confirm the benefits of successful recanalization and attempting of PCI for CTO lesions.

Subjects and Methods

The investigator followed the PRISMA statement for meta-analysis in health care interventions [16] and performed the analysis in accordance with the Meta-Analysis of Observational Studies in Epidemiology guidelines in describing all stages design, implementation, and reporting of this meta-analysis [17].

Data sources and searches

Relevant studies were identified through electronic searches of MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 2003 through to 31 March 2016. Medical subject headings and keyword searches included chronic total occlusion, stent, angioplasty, and percutaneous coronary intervention. Reference lists of selected articles were reviewed for other potentially relevant citations.

Table 1: Characteristics of included studies.

Study	Year	Study period	Subject number	Design	Definition of CTO	Successful PCI	Type of stents	Primary outcomes	Follow-up (months)
Olivari, et al. [5]	2003	1999~2000	286/83	Multicenter, prospective	TIMI 0 or 1, duration >30 days	TIMI 2 or 3, RS <50%, no MACE	BMS	Success, MACE, Symptom status	12
Hoye, et al. [4]	2005	1992~2002	567/304	Single center, retrospective	TIMI 0 or 1, duration >1 month	RS <50%	Stent in the majority	MACE (death, non-fatal AMI, and repeat revascularization)	60
Arslan, et al. [24]	2006	1999~2003	117/115	Single center, retrospective	TIMI 0, duration >3 months	NA	Stents (91.5%)	All-cause death	32
Aziz, et al. [25]	2007	2000~2004	377/166	Single center, retrospective	TIMI 0 or 1, duration >3 months	RS <30%, TIMI 3, no dissection	BMS (80.5%), DES (17.3%)	All-cause death	24
Valenti, et al. [31]	2008	2003~2006	344/142	Single center, retrospective	TIMI 0, duration >3 months	RS <30%, TIMI 3, no complication	SES (42%), PES (58%)	Cardiac survival	24
de Labrioll, et al. [27]	2008	2003~2005	127/45	Single center, retrospective	TIMI 0, duration ≥3 months	TIMI 3, RS <30%	Stents (93.7%), DES (64.1%)	Success, In-hospital complications, MACE (death, MI, TVR)	24
Chen, et al. [26]	2009	2004~2005	132/20	Multicenter, prospective	TIMI 0 or 1, duration >3 months	TIMI 3, RS <20%	DES (95.5%)	MACE (cardiac death, MI, and TVR)	36
Mehran, et al. [29]	2011	1998~2007	1226/565	Multicenter, retrospective	TIMI 0, duration >3 months	RS <50%, TIMI ≥2	BMS (34.1%), DES (65.9%)	MACE (all-cause death, MI, or TVR)	60
Lee, et al. [8]	2011	2003~2006	251/82	Multicenter, retrospective	TIMI 0, duration ≥3 months	TIMI 3, RS <30%	SES (75.7%), PES (24.3%)	MACE (death, MI, or TVR)	36
Niccoli, et al. [13]	2012	2005~2009	196/121	Multicenter, retrospective	TIMI 0, duration >3 months	TIMI 3, RS <30%	SES (60%), PES (40%)	MACE (cardiac death, MI, and repeat revascularization)	36
Jones, et al. [12]	2012	2003~2010	582/254	Single center, retrospective	TIMI 0, duration ≥3 months	TIMI ≥2, RS ≤30%	BMS (23.9%), DES (76.1%)	Long-term mortality, further revascularization	60
Borgia, et al. [11]	2012	2003~2009	237/65	Single center, retrospective	TIMI 0, duration >3 months	TIMI ≥2	DES (98.2%)	Cardiac death, MACE (cardiac death, MI, TVR)	48
Jolicoeu, et al. [19]	2012	1999-2008	213/133	Single center, retrospective	TIMI 0 or 1, duration >7 days	RS <40%, TIMI 3, no complication	BMS (50.7%), DES (51.6%)	Composite endpoint of death and cardiovascular rehospitalization	60
Yang, et al. [14]	2013	2005~2008	87/49	Single center, retrospective	TIMI 0	RS <20%, TIMI 3, no complication	DES	Cardiac mortality, MACE (death, recurrent MI, repeat revascularization), HF rehospitalization	24
Ciećwierz, et al. [18]	2013	2005~2007	138/139	Single center, retrospective	TIMI 0 or 1, duration ≥1 month	TIMI 3, RS <10%	DES, BMS	Death, non-fatal MI and MACE (death, non-fatal MI, and symptom driven-revascularization)	24
Yamamoto, et al. [20]	2013	2005~2007	1192/332	Multicenter, retrospective	TIMI 0 or 1, duration >1 month	TIMI 2 or 3, RS <50%	BMS (22%), DES (78%)	All-cause death	36
Kim, et al. [28]	2014	2007~2009	2045/524	Multicenter, retrospective	TIMI 0, duration >3 months	TIMI ≥2, RS ≤30%	SES (35.5%), PES (30%), ZES (21.9%), EES (12.7%)	Composite of cardiac death and MI	24
Valenti, et al. [30]	2014	2003~2012	58/111	Single center, retrospective	TIMI 0, duration >3 months	TIMI 3, RS <30%	DES	1-year and 3-year cardiac survival	36
Lee, et al. [15]	2016	2003~2014	1004/169	Single center, retrospective	TIMI 0, duration ≥3 months	TIMI 3, RS <30%	DES (1 st 46.1%, 2 nd 53.9%)	All-cause mortality, composite of all-cause death or MI	60

Data are presented as success/failure.

BMS: Bare-Metal Stents; CTO: Chronic Total Occlusion; DES: Drug-Eluting Stents; EES: Everolimus-Eluting Stents; MACE: Major Adverse Cardiac Events; MI: Myocardial Infarction; NA: Not Available; PES: Paclitaxel-Eluting Stents; RS: Residual Stenosis; SES: Sirolimus-Eluting Stents; TIMI: Thrombolysis in Myocardial Infarction; TVR: Target Vessel Revascularization; ZES: Zotarolimus-Eluting Stents

Study selection and data extraction

The investigator (J.-S.J.) conducted the literature search, data extraction, and quality assessment by using a standardized data extraction form. Selected publications were reviewed by the same investigators to assess if studies met the inclusion criteria:

randomized or observational studies comparing clinical outcomes of successful versus unsuccessful recanalization of CTO lesions after coronary stent implantation. The minimum follow-up period required for inclusion was one year. Studies including patients treated with balloon angioplasty alone were excluded from the inclusion.




Figure 1: Trial flow chart shows number of studies retrieved by individual searches and number of trials included in review.

Relevant information was extracted from the articles including patient characteristics (mean age, gender distribution, risk factors), study period, study design, publication year, sample size, type of stent used, left ventricular ejection fraction, and duration of follow-up.

End points

The end points of this study were all-cause mortality, Myocardial Infarction (MI), Major Adverse Cardiac Events (MACE), and incidence of Coronary Artery Bypass Surgery (CABG) at the available follow-up. CTO was defined as a complete obstruction of the vessel exhibiting Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 or 1 and an estimated duration of ≥3 months except 5 study [4,5,18-20] which required from 7 to 30 days’ occlusion for its definition. Death was defined as mortality from any cause. The trial-specific definitions of MI and MACE were used because of different definition across studies. Successful recanalization of CTO was defined as restoration of TIMI flow grade 2 or 3 with a residual stenosis ≤20~50% after stent implantation without procedural complications.

Data synthesis and analysis

Random effects models were used to produce across-study summary Odds Ratios (ORs) with 95% Confidence Intervals (CIs). All p values were 2-tailed, with statistical significance set at 0.05. Statistical heterogeneity was assessed between trials with *I*² statistic, which is derived from Cochran’s Q and the degree of freedom

Table 2: Characteristics of patients.

Study	Age	Male gender (%)	Hypertension (%)	Diabetes (%)	Hyperlipidemia (%)	Current smoker (%)	Prior MI (%)	Prior PCI (%)	Prior CABG (%)	ACS (%)	LVEF (%)
Olivari, et al. [5]	58/59	86/85	53/54	17/20	59/56	37/30	69/69	11/18	5/7	18/5	56/56
Hoye, et al. [4]	60/61	74/74	20/21	12/9	49/43	NA	56/49	24/23	9/10	NA	NA
Arslan, et al. [24]	61/60	75/75	27/24	26/24	27/24	35/38	40/45	NA	NA	NA	50/50
Aziz, et al. [25]	59/59	76/81	48/57	14/9	91/88	18/21	58/58	3/5	4/7	12/19	53/53
Valenti, et al. [31]	67/70	81/83	57/57	24/21	50/51	20/22	45/54	25/30	8/18	39/32	42/41
de Labrioll, et al. [27]	61/64	72/87	82/80	19/41	94/80	21/11	21/22	24/29	12/16	58/53	50/48
Chen, et al. [26]	64/68	74/80	76/65	26/25	20/20	35/35	46/65	NA	NA	80/90	45/42
Mehran, et al. [29]	61/62	85/89	60/59	23/22	66/61	23/28	47/56	NA/NA	14/21	NA/NA	54/53
Lee, et al. [8]	59/64	77/71	50/50	31/31	22/28	34/32	18/29	16/33	NA/NA	41/31	56/55
Niccoli, et al. [13]	64/66	82/88	70/66	34/37	54/47	42/31	32/26	NA/NA	15/10	NA/NA	NA/NA
Jones, et al. [12]	63/64	76/79	64/67	27/29	56/61	NA/NA	32/36	21/36	7/17	NA/NA	56/54
Borgia, et al. [11]	64/65	82/82	60/61	26/31	75/89	36/36 (current or former)	58/60	36/42	14/31	8/7	53/53
Jolicoeu, et al. [19]	58/61	70/79	70/74	33/26	66/71	53/50	21/29	24/18	18/28	NA	56/55
Yang, et al. [14]	66/69	82/82	70/76	36/37	20/22	39/37	26/33	NA	NA	NA	46/47
Ciećwierz, et al. [18]	62/62	80/80	62/57	23/19	38/33	12/12	NA	NA	NA	NA	NA
Yamamoto, et al. [20]	67/66	78/66	83/87	42/42	NA	33/36	32/24	NA	NA	9/19	56/54
Kim, et al. [28]	63/64	73/77	63/63	35/38	38/36	32/30	13/19	24/31	2/5	43/44	NA
Valenti, et al. [30]	64/69	85/73	55/67	17/15	36/41	50/30	19/29	NA	2/10	91/87	36/38
Lee, et al. [15]	59/61	83/83	60/65	31/32	64/59	27/23	8/14	20/21	3/4	27/21	58/58

Data are presented as success/failure. *p<0.05.

CABG: Coronary Artery Bypass Grafting; LVEF: Left Ventricular Ejection Fraction; MI: Myocardial Infarction; NA: Not Available; PCI: Percutaneous Coronary Intervention.

[100×(Q-df)/Q] [21]. *I*² values greater than 25%, 50%, and 75% were considered evidence of low, moderate, and severe statistical heterogeneity, respectively. In case of heterogeneity across the studies, I performed sensitivity analyses, serially excluding studies to determine the source of heterogeneity. The likelihood of publication bias was examined by visual inspection of constructed funnel plot for the all-cause mortality and mathematically by means of Egger’s test (*p* for significant asymmetry <0.1) [22]. For specific evaluation of the presence and extent of publication bias, I used trim-and-fill method according to Duval and Tweedie [23], which imputes missing studies in the funnel plot based on symmetry assumptions. All statistical analyses were performed using the Review Manager Version 5.2 (The Nordic Cochrane Center, Copenhagen, Denmark) and MIX version 2.0 (Biostat XL, Sunnyvale, CA, USA).

Results

A total of 422 publications were reviewed and 32 articles were selected for inclusion and further evaluation. Subsequently, 19 clinical studies were included into the final analysis (Figure 1) [4,5,8,11-15,18-20,24-31]. Characteristics of the included studies are summarized in (Table 1). Of the 12,598 patients, 9,179 patients comprised the successful PCI group and 3,419 patients comprised the unsuccessful PCI group. The success rate of CTO intervention was 72.9% in our study. Seven studies [5,8,13,20,26,28,29] were multicenter trials whereas the other studies [4,8,11,12,14,15,18,19,24, 25,27,31] were single center trials. Baseline characteristics of patients are summarized in (Table 2). To identify possible differences between groups, preprocedural prevalence of risk factors (hypertension, diabetes, and hyperlipidemia), left ventricular ejection fraction, and proportion of patients with acute coronary syndrome were extracted and compared (Table 2). Proportion of patients with multivessel disease and location of involved coronary arteries were presented in (Supplementary Table 1).

All-cause mortality

Eighteen studies reported all-cause mortality. There were 455 (5.0%) deaths of 9,041 patients after successful CTO recanalization

compared to 339 (10.3%) among 3,280 patients after unsuccessful CTO recanalization, corresponding to 52% relative reduction with successful recanalization (OR 0.48, 95% CI 0.38 to 0.61, *p*<0.001; (Figure 2)). The Number Needed to Treat (NNT) to prevent with 1 death with successful CTO recanalization of CTO was 20. Mild statistical heterogeneity was noted among the trials (heterogeneity $\chi^2 = 30.35$, *I*² = 43 %, *p* = 0.03). The sensitivity analysis limited to the 7 multicenter studies [5,8,13,20,26,28,29] did not change the significance of the overall estimates (OR 0.60, 95% CI 0.45-0.82, *p* = 0.001). The sensitivity analysis of the risk of mortality with successful recanalization after exclusion of one study at a time yielded effect sizes similar in magnitude and direction to the overall estimates.

Myocardial infarction

Sixteen studies reported data on MI [4,5,8,11,13-15,19,20,24,26-31]. Two hundred fifty total MI occurred among the 8,082 patients with successful CTO recanalization and 156 in the 2,860 patients with unsuccessful recanalization. The risk of MI at 12 to 60 months was significantly lower in successful PCI group (OR 0.67, 95% CI 0.46 to 0.97, *p* = 0.05; (Figure 3)). Statistical heterogeneity was noted among the included studies (heterogeneity $\chi^2 = 26.87$, *I*² = 48%, *p* = 0.02).

Major adverse cardiac events

Sixteen studies including 9,694 patients were included for the analysis of MACE [4,5,8,11,13-15,18,19,24,26-31]. Overall, 1,071 among 7,028 patients with successful CTO recanalization developed MACE compared with 749 among 2,666 patients after unsuccessful recanalization. Successful CTO recanalization was associated with a significantly lower incidence of MACE compared to the patients with unsuccessful recanalization (OR 0.55, 95% CI 0.42 to 0.73, *p*<0.001; (Figure 4)). Statistical heterogeneity was observed across the studies (heterogeneity $\chi^2 = 69.63$, *I*²=78%, *p*<0.001).

Coronary Artery Bypass Graft Surgery (CABG) and angina relief

Fifteen studies reported CABG [4,5,11-15,18-20,25,28-31] and the pooled analysis showed a consistent 86% relative reduction in the incidence of CABG with successful recanalization of CTO lesions




Figure 2: ORs for all-cause mortality with successful versus unsuccessful recanalization of CTO. The incidence of all-cause mortality was lower in successful recanalization group. CI: Confidence Interval; OR: Odds Ratio; M-H: Mantel-Haenszel




Figure 3: ORs for MI with successful versus unsuccessful recanalization of CTO. The risk of MI did not differ significantly between the two groups. CI: Confidence Interval; OR: Odds Ratio; M-H: Mantel-Haenszel.




Figure 4: ORs for MACE with successful versus unsuccessful recanalization of CTO. Successful CTO recanalization was associated with a significantly lower incidence of MACE compared to the patients with unsuccessful recanalization. CI: Confidence Interval; OR: Odds Ratio; M-H: Mantel-Haenszel.

(OR 0.14, 95% CI 0.10 to 0.20, $p < 0.001$; (Figure 5)). Nine patients were needed to treat with successful CTO recanalization to prevent 1 CABG. Statistical heterogeneity was observed among the included studies (heterogeneity $\chi^2 = 38.61$, $I^2 = 64\%$, $p < 0.001$). Data about relief of angina symptom by successful CTO recanalization was reported in 3 studies. Successful CTO PCI was associated with a significantly higher angina relief compared to the patients with unsuccessful recanalization (OR 7.47, 95% CI 2.43 to 22.93, $p < 0.001$).

Publication bias

Assessment of publication bias using OR of all-cause mortality of the included studies demonstrates a symmetric funnel plot with no evidence of publication bias (Figure 6), confirmed by means of a negative Egger’s regression-based test ($p = 0.11$). The trim-and-fill method indicated that 5 studies were needed to achieve a symmetrical funnel plot.

Discussion

In the present meta-analysis, the investigator found that successful recanalization of CTO was associated with lower all-cause mortality

and risk of MACE. In addition, successful CTO PCI reduced the need for a subsequent CABG by 86%. Our study includes the largest cohort to date and demonstrates statistically significant survival benefit in favor of successful recanalization of CTO using coronary stent implantation.

Because CTO is present in at least one coronary artery in approximately one third among patients undergoing PCI [2,32] improving symptoms and clinical outcomes through successful recanalization of these patients have been one of the major challenges of interventional cardiologists. The principal barrier to CTO PCI has been procedural failure due to a failure to cross the culprit lesion with guide wire or balloon catheter [2,33]. However, the remarkable development of devices and techniques in CTO PCI as well as increased operator experiences have led to higher rates of successful recanalization of CTO vessels [34-36]. Moreover, coronary stents significantly increased long-term patency of recanalized vessel and drug-eluting stents have further improved angiographic outcomes [37,38]. Pancholy, et al. [39] have performed a meta-analysis including 13 observational studies comparing successful versus




Figure 5: ORs for need of CABG with successful versus unsuccessful recanalization of CTO. Pooled analysis showed a consistent 86% relative reduction with successful recanalization of CTO lesions.
 CI: Confidence Interval; OR: Odds Ratio; M-H: Mantel-Haenszel.




Figure 6: Funnel plots for assessment of publication bias. Assessment of publication bias using ORs of all-cause mortality illustrates a symmetrical funnel plots with no evidence of publication bias confirmed by negative Egger's test (p = 0.11). The trim-and-fill method indicated that 5 missing study was needed to achieve a symmetrical funnel plot.
 CI: Confidence Interval; OR: Odds Ratio; M-H: Mantel-Haenszel.

unsuccessful CTO PCI. They reported that successful recanalization of CTO was associated with a significant reduction in short (OR 0.218, 95% CI 0.095 to 0.498) and long-term mortality (OR 0.391, 95% CI 0.311 to 0.493) compared to unsuccessful CTO PCI. Although the authors intended to exclude studies with balloon angioplasty alone without stenting or studies using stents in <70% of patients, studies with limited use of stent-based PCI could not be completely excluded. Results of the present study correspond to those of the previous studies [39-41]. However, analyses of 19 clinical studies from the present work, including >12,000 patients, further support the benefits of successful CTO recanalization with an OR of 0.48 for all-cause mortality in favor of successful recanalization as compared with unsuccessful recanalization without profound heterogeneity or evidence of publication bias. In addition, coronary stents data were extracted exclusively from the included studies and excluded studies using stents in less than 70% of patients.

It is well known that the presence of a CTO in patients suffering from acute anterior MI increase mortality [42]. Hence, successful restoration of blood flow might have potential to reduce fatal complications during a subsequent infarct. In addition, the presence of a CTO is a risk factor for incomplete revascularization, which increase mortality compared to complete revascularization [43]. However, improved long-term survival from complete revascularization in the presence of CTO might not solely stem from higher recanalization rates itself, but also related with several other factors like patients' comorbidities, extent of viable myocardium, and global left ventricular function. Despite unclear prognostic implication, restoration of blood flow by successful recanalization of true lumen help improve left ventricular function, [10,44,45] decrease predisposition to fatal arrhythmias [2], and reduce risk of adverse clinical outcomes. However, it is still unclear whether increased rate of successful restoration of blood flow to the occluded true lumen

may directly extrapolate into increased survival in patients with long-standing CTO lesion. Lee, et al. [15] reported that the survival and Q-wave MI rates during 4.6 years follow-up period were not significantly differ whether patients received a successful or failed CTO PCI in their longitudinal experience of consecutive CTO procedures over 11 years.

In this study, clinical outcomes of patients after successful recanalization of CTOs were better and our results further supports the evidence suggesting a survival advantage of successful recanalization compared with unsuccessful PCI. The result of our study corresponds to previous studies reporting similar incidence of MI [7,41]. However, benefits of opening CTO successfully by PCI might not be compared with PCI failure and the resultant ominous outcomes that frequently accompany several complications. There is an urgent need for randomized trials in view of the potential for medical treatment of CTO to reduce adverse clinical events when compared to the attempt to negotiate CTO lesions. The DECISION-CTO (Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients with Chronic Total Occlusion trial; NCT01078051) is currently underway and I expect this study might address the definitive proof of a beneficial effect of successful CTO PCI.

The present study has several limitations to be addressed. First, included studies are relatively small and heterogeneous in size. Second, I could not have access to patient-level data to predict which subgroup of patients could achieve better outcomes after successful recanalization of CTO. There might be wide variability in risk profile and lesion complexity of the included patients. Patients with unsuccessful recanalization are more likely to have heavy calcifications and long lesions [5,46]. Furthermore, there was no data comparing post-interventional medical treatment between patients with successful versus unsuccessful recanalization of CTO. Third, definitions of CTO, successful recanalization of CTO, and end points were different across the included studies. Fourth, some results of the present meta-analysis have significant heterogeneity, which is frequent in meta-analysis performed on global data. Thus, I tried to overcome heterogeneity by sensitivity analysis according to study design. Fifth, proportion of patients who received stents and types of used stents were different among the included studies. Finally, in spite of highly selective tools for retrieval of eligible studies from database search, some relevant studies might have been overlooked.

Conclusion

This meta-analysis suggested that successful recanalization of CTO lesions using coronary stent is associated with improvement in all-cause mortality, and the need for subsequent CABG compared to unsuccessful CTO PCI. Adequately powered randomized trials to assess patient-oriented outcomes should be conducted in order to definitely assess the efficacy of CTO recanalization in participants with different risk profiles and lesion complexities.

References

- Grantham JA, Marso SP, Spertus J, House J, Holmes DR Jr, Rutherford BD. Chronic total occlusion angioplasty in the United States. *JACC Cardiovasc Interv.* 2009; 2: 479-486.
- Stone GW, Reifart NJ, Moussa I, Hoyer A, Cox DA, Colombo A, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. *Circulation.* 2005; 112: 2530-2537.
- Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi LV, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. *J Am Coll Cardiol.* 2001; 38: 409-414.
- Hoyer A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992-2002. *Eur Heart J.* 2005; 26: 2630-2636.
- Olivari Z, Rubartelli P, Piscione F, Etori F, Fontanelli A, Salemm L, et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). *J Am Coll Cardiol.* 2003; 41: 1672-1678.
- Puma JA, Sketch MH Jr, Tchong JE, Harrington RA, Phillips HR, Stack RS, et al. Percutaneous revascularization of chronic coronary occlusions: an overview. *J Am Coll Cardiol.* 1995; 26: 1-11.
- Joyal D, Afialo J, Rinfret S. Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. *Am Heart J.* 2010; 160: 179-187.
- Lee SW, Lee JY, Park DW, Kim YH, Yun SC, Kim WJ, et al. Long-term clinical outcomes of successful versus unsuccessful revascularization with drug-eluting stents for true chronic total occlusion. *Catheter Cardiovasc Interv.* 2011; 78: 346-353.
- Prasad A, Rihal CS, Lennon RJ, Wiste HJ, Singh M, Holmes DR. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. *J Am Coll Cardiol.* 2007; 49: 1611-1618.
- Sirnes PA, Myreng Y, Molstad P, Bonarjee V, Golf S. Improvement in left ventricular ejection fraction and wall motion after successful recanalization of chronic coronary occlusions. *Eur Heart J.* 1998; 19: 273-281.
- Borgia F, Viceconte N, Ali O, Stuart-Buttle C, Saraswathyamma A, Parisi R, et al. Improved cardiac survival, freedom from MACE and angina-related quality of life after successful percutaneous recanalization of coronary artery chronic total occlusions. *Int J Cardiol.* 2012; 161: 31-38.
- Jones DA, Weerackody R, Rathod K, Behar J, Gallagher S, Knight CJ, et al. Successful recanalization of chronic total occlusions is associated with improved long-term survival. *JACC Cardiovasc Interv.* 2012; 5: 380-388.
- Niccoli G, De Felice F, Belloni F, Fiorilli R, Cosentino N, Fracassi F, et al. Late (3 years) follow-up of successful versus unsuccessful revascularization in chronic total coronary occlusions treated by drug eluting stent. *Am J Cardiol.* 2012; 110: 948-953.
- Yang ZK, Zhang RY, Hu J, Zhang Q, Ding FH, Shen WF. Impact of successful staged revascularization of a chronic total occlusion in the non-infarct-related artery on long-term outcome in patients with acute ST-segment elevation myocardial infarction. *Int J Cardiol.* 2013; 165: 76-79.
- Lee PH, Lee SW, Park HS, Kang SH, Bae BJ, Chang M, et al. Successful Recanalization of Native Coronary Chronic Total Occlusion Is Not Associated With Improved Long-Term Survival. *JACC Cardiovasc Interv.* 2016; 9: 530-538.
- Liberati A, Altman DG, Tetzlaff J, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ.* 2009; 339: b2700.
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. *JAMA.* 2000; 283: 2008-2012.
- Cieciewicz D, Jaguszewski M, Fijalkowski M, Targoński R, Masiewicz E, Duda M, et al. Successful recanalisation of isolated chronic total occlusions improves outcomes in long-term observation: a case-control study. *Kardiol Pol.* 2013; 71: 1013-1020.
- Jolicoeur EM, Sketch MJ, Wojdyla DM, Javaheri SP, Nosib S, Lokhnygina Y, et al. Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions. *Catheter Cardiovasc Interv.* 2012;

- 79: 603-612.
20. Yamamoto E, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Ono K, et al. Long-term outcomes after percutaneous coronary intervention for chronic total occlusion (from the CREDO-Kyoto registry cohort-2). *Am J Cardiol.* 2013; 112: 767-774.
 21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003; 327: 557-560.
 22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ.* 1997; 315: 629-634.
 23. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics.* 2000; 56: 455-463.
 24. Arslan U, Balcioglu AS, Timurkaynak T, Cengel A. The clinical outcomes of percutaneous coronary intervention in chronic total coronary occlusion. *Int Heart J.* 2006; 47: 811-819.
 25. Aziz S, Stables RH, Grayson AD, Perry RA, Ramsdale DR. Percutaneous coronary intervention for chronic total occlusions: improved survival for patients with successful revascularization compared to a failed procedure. *Catheter Cardiovasc Interv.* 2007; 70: 15-20.
 26. Chen SL, Ye F, Zhang JJ, Lin S, Zhu ZS, Tian NL, et al. Clinical outcomes of percutaneous coronary intervention for chronic total occlusion lesions in remote hospitals without on-site surgical support. *Chin Med J.* 2009; 122: 2278-2285.
 27. De Labriolle A, Bonello L, Roy P, Lemesle G, Steinberg DH, Xue Z, et al. Comparison of safety, efficacy, and outcome of successful versus unsuccessful percutaneous coronary intervention in "true" chronic total occlusions. *Am J Cardiol.* 2008; 102: 1175-1181.
 28. Kim BK, Shin S, Shin DH, Hong MK, Gwon HC, Kim HS, et al. Clinical outcome of successful percutaneous coronary intervention for chronic total occlusion: results from the multicenter Korean Chronic Total Occlusion (K-CTO) registry. *J Invasive Cardiol.* 2014; 26: 255-259.
 29. Mehran R, Claessen BE, Godino C, Dangas GD, Obunai K, Kanwal S, et al. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. *JACC Cardiovasc Interv.* 2011; 4: 952-961.
 30. Valenti R, Marrani M, Cantini G, Migliorini A, Carrabba N, Vergara R, et al. Impact of chronic total occlusion revascularization in patients with acute myocardial infarction treated by primary percutaneous coronary intervention. *Am J Cardiol.* 2014; 114: 1794-1800.
 31. Valenti R, Migliorini A, Signorini U, Vergara R, Parodi G, Carrabba N, et al. Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion. *Eur Heart J.* 2008; 29: 2336-2342.
 32. Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. *Am Heart J.* 1993; 126: 561-564.
 33. Kinoshita I, Katoh O, Nariyama J, Otsuji S, Tateyama H, Kobayashi T, et al. Coronary angioplasty of chronic total occlusions with bridging collateral vessels: immediate and follow-up outcome from a large single-center experience. *J Am Coll Cardiol.* 1995; 26: 409-415.
 34. Saito S, Tanaka S, Hiroe Y, Miyashita Y, Takahashi S, Satake S, et al. Angioplasty for chronic total occlusion by using tapered-tip guidewires. *Catheter Cardiovasc Interv.* 2003; 59: 305-311.
 35. Whitlow PL, Burke MN, Lombardi WL, Wyman RM, Moses JW, Brilakis ES, et al. Use of a novel crossing and re-entry system in coronary chronic total occlusions that have failed standard crossing techniques: results of the FAST-CTOs (Facilitated Antegrade Steering Technique in Chronic Total Occlusions) trial. *JACC Cardiovasc Interv.* 2012; 5: 393-401.
 36. Lombardi WL. Retrograde PCI: what will they think of next? *J Invasive Cardiol.* 2009; 21: 543.
 37. Saeed B, Kandzari DE, Agostoni P, Lombardi WL, Rangan BV, Banerjee S, et al. Use of drug-eluting stents for chronic total occlusions: a systematic review and meta-analysis. *Catheter Cardiovasc Interv.* 2011; 77: 315-332.
 38. Rubartelli P, Verna E, Niccoli L, Giachero C, Zimarino M, Bernardi G, et al. Coronary stent implantation is superior to balloon angioplasty for chronic coronary occlusions: six-year clinical follow-up of the GISSOC trial. *J Am Coll Cardiol.* 2003; 41: 1488-1492.
 39. Pancholy SB, Boruah P, Ahmed I, Kwan T, Patel TM, Saito S. Meta-analysis of effect on mortality of percutaneous recanalization of coronary chronic total occlusions using a stent-based strategy. *Am J Cardiol.* 2013; 111: 521-525.
 40. Christakopoulos GE, Christopoulos G, Carlino M, Jeroudi OM, Roesle M, Rangan BV, et al. Meta-analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total occlusions. *Am J Cardiol.* 2015; 115: 1367-1375.
 41. Khan MF, Wendel CS, Thai HM, Movahed MR. Effects of percutaneous revascularization of chronic total occlusions on clinical outcomes: a meta-analysis comparing successful versus failed percutaneous intervention for chronic total occlusion. *Catheter Cardiovasc Interv.* 2013; 82: 95-107.
 42. Van der Schaaf RJ, Vis MM, Sjauw KD, Koch KT, Baan J Jr, Tijssen JG, et al. Impact of multivessel coronary disease on long-term mortality in patients with ST-elevation myocardial infarction is due to the presence of a chronic total occlusion. *Am J Cardiol.* 2006; 98: 1165-1169.
 43. Tamburino C, Angiolillo DJ, Capranzano P, Dimopoulos K, La Manna A, Barbagnano R, et al. Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents. *Catheter Cardiovasc Interv.* 2008; 72: 448-456.
 44. Baks T, Van Geuns RJ, Duncker DJ, Cademartiri F, Mollet NR, Krestin GP, et al. Prediction of left ventricular function after drug-eluting stent implantation for chronic total coronary occlusions. *J Am Coll Cardiol.* 2006; 47: 721-725.
 45. Kirschbaum SW, Baks T, Van den Ent M, Sianos G, Krestin GP, Serruys PW, et al. Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions. *Am J Cardiol.* 2008; 101: 179-185.
 46. Noguchi T, Miyazaki MS, Morii I, Daikoku S, Goto Y, Nonogi H. Percutaneous transluminal coronary angioplasty of chronic total occlusions. Determinants of primary success and long-term clinical outcome. *Catheter Cardiovasc Interv.* 2000; 49: 258-264.